Human islet amyloid polypeptide transgenic mice as a model of non-insulin-dependent diabetes mellitus (NIDDM)

FEBS Lett. 1993 May 24;323(1-2):40-4. doi: 10.1016/0014-5793(93)81444-5.

Abstract

To model islet amyloidogenesis in NIDDM and explore the glucoregulatory role of islet amyloid polypeptide (IAPP), we have created transgenic mice containing a rat insulin-I promoter-human IAPP fusion gene. Expression of human IAPP was localized to the islets of Langerhans, anterior pituitary and brain in transgenic animals; blood IAPP levels were elevated 5-fold while fasting glucose levels remained normal. Amyloid deposits have not been detected in transgenic islets suggesting that other co-existing abnormalities in NIDDM may be required for the formation of islet amyloid. These animals provide a unique model for exploring this hypothesis and other proposed functions of IAPP.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyloid / blood
  • Amyloid / genetics
  • Amyloid / physiology*
  • Animals
  • Blotting, Northern
  • Blotting, Western
  • Diabetes Mellitus, Type 2*
  • Disease Models, Animal
  • Female
  • Fluorescent Antibody Technique
  • Humans
  • Islet Amyloid Polypeptide
  • Islets of Langerhans / physiology*
  • Male
  • Mice
  • Mice, Transgenic
  • Rats

Substances

  • Amyloid
  • Islet Amyloid Polypeptide